Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Blood microRNA-7 as a Progression Biomarker in men with Parkinson's disease
Movement Disorders
S37 - Movement Disorders: Phenotyping and Biomarkers (2:00 PM-2:12 PM)
006
Animal models have shown that MiR-7-5p regulates alpha-synuclein (α-syn) translation, transcription and autophagy, in addition to NLRP3 inflammasome activity. Furthermore, MiR-7-5p is diminished in the substantia nigra and the peripheral blood of PD patients.

To investigate the use of microRNA-7-5p (miR-7-5p) as a potential biomarker for Parkinson's disease (PD) progression.

Data was obtained at two longitudinal points (Baseline and 36 months) from 315 (208 male/107 female) drug-naïve PD patients and 160 (108 male /52 female) age- and sex-matched healthy controls (HC) from the Parkinson's Progression Marker Initiative (PPMI). Whole blood miR-7-5p was longitudinally correlated with a) clinical assessment tools (MDS-UPDRS motor and total scores), b) markers of inflammation (NLRP3 mRNA, IL-1β mRNA, and NfL), and c) α-syn expression (α-syn mRNA, CSF α-syn). Analyses were done using rmcorr in R.

MiR-7-5p levels decreased by 17% in PD patients over 36 months. Longitudinal, Ln miR-7-5p had a strong negative correlation with MDS-UPDRS-motor and total scores in men with PD and with NfL for all PD subjects. There was no correlation between miR-7-5p and CSF α-syn protein in either group.

Our data demonstrate the importance of gender differences in biomarker discovery and suggest a robust association between lower levels of miR-7-5p and markers of clinical progression in men with PD. These findings support the use of miR-7-5p as a progression biomarker, which could lead to a quantifiable tool for disease-modifying therapies.

Authors/Disclosures
Mya C. Schiess, MD (Univ of Texas-Houston Med School)
PRESENTER
Dr. Schiess has nothing to disclose.
Jessika Suescun, MD (University of Texas) Dr. Suescun has nothing to disclose.
Kelly Lauren Block, DO Dr. Block has nothing to disclose.
Emily Tharp, MD Dr. Tharp has nothing to disclose.
Timothy Michael Ellmore, PhD (The City College of New York) The institution of Prof. Ellmore has received research support from NIMH.
Mohammad Shahnawaz, PhD (University of Texas Health Science Center At Houston) The institution of Dr. Shahnawaz has received research support from American Parkinson Disease Association. The institution of Dr. Shahnawaz has received research support from NIH. The institution of Dr. Shahnawaz has received research support from Texas Alzheimer's Research & Care Consortium . Dr. Shahnawaz has received intellectual property interests from a discovery or technology relating to health care.
Christopher Adams, MD (The University of Washington) Dr. Adams has stock in Medtronic.